Crescent Biopharma (CBIO) vs CorMedix (CRMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Crescent Biopharma (CBIO) has outperformed CorMedix (CRMD) over the past year, gaining 17.1% versus a loss of 35.0%. Over five years, CRMD leads with a +47.9% price change compared with -92.9% for CBIO. CorMedix is the larger company by market cap ($570.6 million vs $524.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CBIO | CRMD |
|---|---|---|
| Share price | $14.12 | $7.32 |
| Market cap | $524.51M | $570.55M |
| 1-day change | +4.67% | +0.55% |
| YTD return | +19.06% | -37.06% |
| 1-year return | +17.08% | -35.05% |
| 5-year return | -92.87% | +47.88% |
| P/E ratio (TTM) | — | 3.57 |
| Forward P/E | — | 20.91 |
| EPS (TTM) | $-7.63 | $2.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.41 | $13.02 |
| 52-week low | $8.72 | $6.13 |
| Distance from 52-week high | -48.49% | -43.78% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +123.09% | +109.43% |
| Average volume | 399.18K | 1.06M |
| Shares outstanding | 37.14M | 77.94M |
| Employees | 69 | 191 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CBIO has outperformed CRMD by 52.1 percentage points over the past year.
About Crescent Biopharma
CBIO stock →Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About CorMedix
CRMD stock →CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Health Care · Biotechnology: Pharmaceutical Preparations · 191 employees
CBIO vs CRMD FAQ
Which is bigger, Crescent Biopharma or CorMedix?
CorMedix (CRMD) is larger, with a market capitalization of $570.55M compared with $524.51M for Crescent Biopharma (CBIO).
Which stock has performed better over the past year, CBIO or CRMD?
CBIO returned +17.08% over the past 12 months, compared with -35.05% for CRMD (price return, excluding dividends). Past performance does not predict future results.
Are Crescent Biopharma and CorMedix in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.